Table F5Targeted Monotherapy

StudyComparisonProgression Free Survival (95% CI), p ValueOverall Response (95% CI), p Value
ReferenceNrand/NevalaAgentsNrand/Nevala
Mok, 20091081217/1177Ge609/597Hazard ratio favoring treatment with gefitinib = 0.74 (95% CI 0.65–0.85)Hazard ratio favoring treatment with gefitinib = 0.91 (95% CI, 0.76–1.10)
CbP608/550
Maemondo, 2010109230/224Ge115/114Hazard ratio favoring treatment with gefitinib = 0.30, 95% CI (0.22–0.41)2 year survival
All patients had EGFR mutationsCbP115/110Ge 61.4%
CbP 46.7% (p=0.31)
Mitsudomi, 2010110177/172Ge86/88Hazard ratio favoring treatment with gefitinib = 0.49 (95% CI 0.34–0.71), p=0.0001Hazard ratio favoring treatment with gefitinib = 0.61 (95% CI 0.28–1.34)
All patients had EGFR mutationsCD86/89
Zhou, 2011112165/154E83/82Hazard ratio favoring treatment with erlotinib = 0.16 (95% CI 0.10–0.26)NR
All patients had EGFR mutationsCbP82/72
Han, 2012111Ge309/159Hazard ratio favoring treatment with gefitinib = 0.83 (95% CI 0.66–1.06), p=0.138Hazard ratio showed no clinically important difference: 1.07 (95% CI 0.82–1.40), p=.604
 Total population313/309GC309/150
 EGFR mutation subgroup--/96Ge--/53Hazard ratio favoring treatment with gefitinib = 0.544 (95% CI 0.27–1.10)Hazard ratio showed no clinically important difference: 0.96 (95% CI 0.46–2.00)
GC--/43
Rosell, 2012113173/173E86/86Hazard ratio favoring treatment with erlotinib = 0.37 (95% CI 0.25–0.54), p<0.0001ratio showed no clinically important difference: 1.04 (95% CI 0.65–1.67), p=0.87
All patients had EGFR mutationsCD or CG87/87
a

Neval only reported when analysis was not intention-to-treat.

From: RESULTS

Cover of Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness [Internet].
Maher AR, Miake-Lye IM, Beroes JM, et al.
Washington (DC): Department of Veterans Affairs (US); 2012 Oct.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.